about
Studies of selective TNF inhibitors in the treatment of brain injury from stroke and trauma: a review of the evidence to dateDiabetic foot syndrome: Immune-inflammatory features as possible cardiovascular markers in diabetesUse of QT intervals for a more accurate diagnose of syncope and evaluation of syncope severity.Neuron protection as a therapeutic target in acute ischemic stroke.Diabetic foot syndrome as a possible cardiovascular marker in diabetic patients.Peripheral frequency of CD4+ CD28- cells in acute ischemic stroke: relationship with stroke subtype and severity markersInflammatory cytokines in acute ischemic stroke.Immune-inflammatory markers and arterial stiffness indexes in subjects with acute ischemic stroke with and without metabolic syndrome.Inflammation as a therapeutic target in acute ischemic stroke treatment.Effects of ACE-inhibitors and angiotensin receptor blockers on inflammation.Effects of physical exercise on inflammatory markers of atherosclerosis.Supraventricular tachycardias: proposal of a diagnostic algorithm for the narrow complex tachycardias.Electrocardiographic diagnosis of atrial tachycardia: classification, P-wave morphology, and differential diagnosis with other supraventricular tachycardias.Sodium thiosulfate not always resolves calciphylaxis: an ambiguous response.Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading.Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables.Appropriateness of requests for human serum albumin at the University Hospital of Palermo, Italy: a prospective study.Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites.HLA and killer cell immunoglobulin-like receptors influence the natural course of CMV infection.Anti-tumour necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behçet's syndrome.Positional brain ischemia with MCA occlusion successfully treated with extra-intracranial bypass.Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.Predictors of outcome in acute ischemic cerebrovascular syndromes: The GIFA study.Different effects of losartan and delapril on plasma PAI-1 levels in patients with mild to moderate hypertension.Identification of a novel mutation in the alpha-galactosidase A gene in patients with Fabry disease.Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events.Familial hypobetalipoproteinemia due to apolipoprotein B R463W mutation causes intestinal fat accumulation and low postprandial lipemia.Immuno-inflammatory and thrombotic/fibrinolytic variables associated with acute ischemic stroke diagnosis.Patients' acceptability of different fentanyl products for breakthrough cancer pain.Arterial stiffness and ischemic stroke in subjects with and without metabolic syndrome.Plasma levels of inflammatory and thrombotic/fibrinolytic markers in acute ischemic strokes: relationship with TOAST subtype, outcome and infarct site.A family with various symptomatology suggestive of Anderson-Fabry disease and a genetic polymorphism of alpha galactosidase A gene.Effects of clinical and laboratory variables at admission and of in-hospital treatment with cardiovascular drugs on short term prognosis of ischemic stroke. The GIFA study.Single nucleotide polymorphisms (SNPs) of pro-inflammatory/anti-inflammatory and thrombotic/fibrinolytic genes in patients with acute ischemic stroke in relation to TOAST subtype.Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease.Novel alpha-galactosidase A mutation in a female with recurrent strokes.Metabolic and anti-inflammatory effects of a home-based programme of aerobic physical exercise.Stroke subtypes and their possible implication in stroke prevention drug strategies.Arterial stiffness indexes in acute ischemic stroke: relationship with stroke subtype.
P50
Q27001147-1DF96631-B6B8-42F7-9438-1D445BC446E5Q28082521-2D14BD30-E54C-41A1-98E5-0C34834F881EQ33163860-576C1801-B98E-4B96-9630-0DA488CFBA66Q35009080-F7C16EF8-92F7-4567-8809-1472E0770A07Q35342114-BBA5183E-6FCE-4907-BFBA-EFF2C01A7D80Q36152969-8C09298F-4839-4596-97C9-F8EA605EA317Q37347436-647C3D93-B498-4274-A1E9-800BB4A6B88EQ37617485-9E518B3D-7C68-40F1-AD7E-77A43D6ED459Q37619626-9044A058-A7ED-4EB7-AF0D-C5A04AD2083CQ37979302-699AD3E5-1A7B-40D4-8F54-D7553C5A4110Q37990568-BE6CAF0C-6727-4ACF-80A0-5BB112AD0264Q38087723-806B0F27-C852-4EE6-B4EF-DDA340DA7206Q38296344-BDFBD88B-3357-4EF2-BBEE-D4C300B738DBQ39273414-02C9EB80-AC88-4EAE-A981-4AD122391C03Q39288641-8E6A33EF-4F32-4023-A204-ED6C70CD2E21Q39396584-0C658F4B-3B5C-442F-B29C-4781ED4DAA88Q39952070-0EDAAA10-59EA-4215-8C16-1A3C69ED199EQ41452348-B4D763A0-F90B-41EC-A351-DF471DEFC98CQ42171043-60A70D00-6745-4CF8-A44F-D8D05DBC5117Q42224225-1062DFE9-E94F-4DB2-865B-4336F6B8F9E8Q42689998-F28481E0-F63F-4758-9D90-FBED923821CBQ43148987-3EEF1FBA-E0E1-494A-B520-28DDC7F6C985Q43691270-FE059CD5-2700-4DF3-BBCD-A01DB477F5ADQ44276792-536489CB-DE75-4BB4-A5AA-74324800173CQ44682935-F1D8B5E1-FC91-4D3C-8DE4-E3FF14A9397EQ44801556-4A15C185-1D6D-439C-B73B-1279ACAB37A5Q45156380-6D085A6D-3528-4541-84BF-5F7CD14C8C3BQ46062174-AF81615D-36A1-41AD-9322-74FC93CC7FB5Q46420379-8AF8C7A7-0282-49F2-9140-AD2990DF0FE5Q47784379-D8C62959-757D-464A-82F5-648D9D664130Q48352636-39F0BA2F-474B-4F6B-82F5-1F2D33E13263Q48479997-EC443EAD-4A2B-4F6B-B6A1-A24359EB5C9DQ48497315-531101E3-8407-480A-9BCE-DF4E30ED24A7Q48569198-2E6CF429-C440-44BC-AA12-C7A00FF6B581Q48611585-D8BC5D2A-B8DA-460F-B423-7D2AB4988FBBQ51004272-A7A568FA-2544-4BF6-A476-4925FE309C51Q51323863-A57427D6-B64F-43EC-A6E7-A714E115EA2BQ51331215-8F495A33-BCAD-4EA7-9D87-629989DDB860Q51755651-01F76BEB-4E18-4CEF-B730-5ECE16528505Q51778529-F7CBE032-3B25-4F8D-90B0-A3A03AD3B746
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Antonino Tuttolomondo
@ast
Antonino Tuttolomondo
@en
Antonino Tuttolomondo
@es
Antonino Tuttolomondo
@nl
type
label
Antonino Tuttolomondo
@ast
Antonino Tuttolomondo
@en
Antonino Tuttolomondo
@es
Antonino Tuttolomondo
@nl
prefLabel
Antonino Tuttolomondo
@ast
Antonino Tuttolomondo
@en
Antonino Tuttolomondo
@es
Antonino Tuttolomondo
@nl
P106
P1153
6602780506
P21
P31
P496
0000-0001-6440-7318